Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest in this topic

  1. Ocular Complications of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors in T2DM Treatments: A Retrospective Real-World Cohort Study 2025-10-11
  2. The growing range of complications of diabetes mellitus 2025-01-03
  3. A systematic review of neurological symptoms and complications of COVID-19 2020-07-20

Studies

7 studies carry this tag.

Date range

1991 to 2025

Top journals

  • Clinical pharmacology and therapeutics 1
  • Journal of hepatology 1
  • Journal of neurology 1
  • Journal of the American Geriatrics Society 1
  • Mini reviews in medicinal chemistry 1

7 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Ocular Complications of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors in T2DM Treatments: A Retrospective Real-World Cohort Study

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Clinical pharmacology and therapeutics 2025-10-11 Drug development

    Glaucoma is a leading cause of irreversible vision loss worldwide, and type 2 diabetes mellitus (T2DM) is increasingly recognized as a risk factor for glaucoma.

  2. The growing range of complications of diabetes mellitus

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Trends in endocrinology and metabolism: TEM 2025-01-03 Drug development

    With the rising prevalence of type 2 diabetes mellitus (T2DM) and obesity, several previously under-recognised complications associated with T2DM are becoming more evident.

  3. A systematic review of neurological symptoms and complications of COVID-19

    ✓ Peer-reviewed alzhub usefulness score 78 out of 100. Journal of neurology 2020-07-20 Tau biomarkers

    The most frequent neurological symptoms reported in association with COVID-19 are non-specific for the infection with SARS-CoV-2.

  4. Radiotherapy for pituitary adenomas: long-term outcome and complications

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Radiation oncology journal 2011-09-30 Risk factors

    Median follow-up was 5.7 years (range, 2 to 14.4 years).

  5. Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Mini reviews in medicinal chemistry 2008-11-01 Drug development

    Type 2 diabetes is a major health problem associated with excess mortality and morbidity.

  6. Complications of cirrhosis III. Hepatic encephalopathy

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of hepatology 2000-01-01 Risk factors

    Hepatic encephalopathy (HE) is a major neuropsychiatric complication of cirrhosis.

  7. Behavioral complications of drug treatment of Parkinson's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of the American Geriatrics Society 1991-07-01 Drug development

    A variety of neuropharmacologic agents, including anticholinergic drugs, amantadine hydrochloride, levodopa, selegiline, bromocriptine, and pergolide, are now available for the treatment of Parkinson's disease.

All topic tags with their study counts